Curative Biotechnology has entered into an agreement with Sterling Pharmaceutical Services to manufacture clinical supply of its metformin-based topical ophthalmic formulation.

Sterling, a U.S.-based contract development and manufacturing organization (CDMO), specializes in the development and production of sterile pharmaceutical products. Under the agreement, Sterling will support the manufacturing of topical metformin ophthalmic drops intended for use in Curative’s planned first-in-human clinical study. The study will be conducted under the company’s Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH).

The manufacturing partnership is expected to support multiple clinical initiatives, including Curative’s phase 1 human trial targeting dry age-related macular degeneration (AMD), as well as a K9 clinical study focused on PDE6-associated retinal degeneration. The latter is a genetic early-onset retinal condition in dogs that may provide valuable translational insights for human retinitis pigmentosa.

“Engaging Sterling Pharmaceutical Services represents an important step in advancing our metformin-based ophthalmology platform toward clinical development,” said Paul Michaels, Executive Chairman of Curative Biotechnology. “We are pleased to be working with an experienced manufacturing partner capable of supporting production of sterile ophthalmic formulations as we prepare for our planned human and K9 clinical studies.”